| 1 |
Miyatani Y, Kobayashi T. De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease. Gut Liver 2023;17:181-9. [PMID: 36375794 DOI: 10.5009/gnl220070] [Reference Citation Analysis]
|
| 2 |
Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 2023;43:421-35. [PMID: 36635577 DOI: 10.1007/s00296-022-05270-6] [Reference Citation Analysis]
|
| 3 |
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, Narula N, Tsai C, Peerani F, Reise-Filteau M, Bressler B, Starkey SY, Loomes D, Sedano R, Jairath V, Bessissow T; Canadian IBD Research Consortium. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol 2023. [PMID: 36580497 DOI: 10.14309/ajg.0000000000002129] [Reference Citation Analysis]
|
| 4 |
Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, Zabana Y, Hinojosa J, Barreiro de Acosta M, Balderramo D, Balfour D, Bellicoso M, Daffra P, Morelli D, Orsi M, Rausch A, Ruffinengo O, Toro M, Sambuelli A, Novillo A, Gomollón F, De Paula JA. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol 2023:S0210-5705(23)00014-6. [PMID: 36731724 DOI: 10.1016/j.gastrohep.2023.01.009] [Reference Citation Analysis]
|
| 5 |
Choi DK, Cohen NA, Choden T, Cohen RD, Rubin DT. Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis 2023:izad012. [PMID: 36715294 DOI: 10.1093/ibd/izad012] [Reference Citation Analysis]
|
| 6 |
Armuzzi A, Hart A, Cappelleri JC, Mammar N, Hur P, Hoskin B, Hennessy F, Milligan G, Dignass A. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC Gastroenterol 2023;23:17. [PMID: 36658481 DOI: 10.1186/s12876-023-02640-7] [Reference Citation Analysis]
|
| 7 |
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne) 2023;10:1089099. [PMID: 36936239 DOI: 10.3389/fmed.2023.1089099] [Reference Citation Analysis]
|
| 8 |
Sleiman J, Bassi M, Tsipotis E, Charabaty A. Medical Treatment Options for Ulcerative Colitis. Clin Colon Rectal Surg 2022;35:428-36. [PMID: 36591395 DOI: 10.1055/s-0042-1758048] [Reference Citation Analysis]
|
| 9 |
Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis 2022:izac222. [PMID: 36242764 DOI: 10.1093/ibd/izac222] [Reference Citation Analysis]
|
| 10 |
Cohen NA, Steinberg JM, Silfen A, Traboulsi C, Rodriguez TG, Singer JM, Patel S, Cohen RD, Dalal SR, Sakuraba A, Pekow J, Micic D, Rubin DT. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci 2022. [PMID: 36242686 DOI: 10.1007/s10620-022-07716-0] [Reference Citation Analysis]
|
| 11 |
Irving PM, Leung Y, Dubinsky MC. Review article: guide to tofacitinib dosing in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:1131-45. [PMID: 35993338 DOI: 10.1111/apt.17185] [Reference Citation Analysis]
|
| 12 |
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program. J Crohns Colitis 2022:jjac141. [PMID: 36124702 DOI: 10.1093/ecco-jcc/jjac141] [Reference Citation Analysis]
|
| 13 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis 2023;29:85-96. [PMID: 35648151 DOI: 10.1093/ibd/izac063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Herrlinger K, Stange EF. JAK-Inhibitoren: eine neue Therapieoption. Gastro-News 2022;9:38-40. [DOI: 10.1007/s15036-022-2479-1] [Reference Citation Analysis]
|
| 16 |
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis 2022;16:2-17. [PMID: 34635919 DOI: 10.1093/ecco-jcc/jjab178] [Cited by in Crossref: 87] [Cited by in F6Publishing: 64] [Article Influence: 87.0] [Reference Citation Analysis]
|
| 17 |
Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
|
| 18 |
Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P, Akanbi O, Tripathi N, Yarra P, Su L, Flomenhoft D, Stromberg A, Barrett TA. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Dig Dis Sci 2021;66:2051-8. [PMID: 32710192 DOI: 10.1007/s10620-020-06486-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
